Notice Regarding the Status (Progress Report) of Acquisition of Own Shares

Press Release

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
(Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)


Osaka, Japan, March 1, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao
Teshirogi, Ph.D.; hereafter “Shionogi”) today announces that it has acquired its own shares pursuant
to the provisions of Article 156 of the Companies Act, applied by replacing terms pursuant to the
provisions of Article 165, paragraph 3 of the same Act. The status (progress report) of the
acquisition is as follows.


1. Class of shares acquired Common stock of the Company
2. Total number of shares acquired 1,684,400 shares
3. Total value of shares acquired 9,830,899,509 yen
4. Period of acquisition
From February 1, 2021 to February 28, 2021 (execution base)
5. Method of acquisition
Acquire in the open market through discretionary trading in Tokyo Stock Exchange


(Reference)
1. Details of the resolution at the meeting of the Board of Directors held on October 30, 2020
(1) Class of shares to be acquired Common stock of the Company
(2) Total number of shares to be acquired 9,500,000 shares (maximum)
(3.1% of total outstanding shares [excluding treasury stock])
(3) Total amount of acquisition cost 50 billion yen (maximum)
(4) Period of acquisition From November 1, 2020 to March 31, 2021


2. The accumulative number and value of own shares acquired pursuant to the resolution above (on
January 31, 2021)
(1) Total number of shares acquired 7,191,200 shares
(2) Total value of shares acquired 40,898,244,997 yen

Forward-looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light
of the information currently available, assumptions that are subject to risks and uncertainties which could
cause actual results to differ materially from these statements. Risks and uncertainties include general
domestic and international economic conditions such as general industry and market conditions, and changes
of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to
product-related forward-looking statements. Product risks and uncertainties include, but are not limited to,
completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about

---

 Press Release
product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and
foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are
manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity
to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims
any intention or obligation to update or revise any forward-looking statements whether as a result of new
information, future events or otherwise.


For further information, contact:
Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885

---